Lung cancer company LUNGevity Foundation disclosed on Monday the promotion of Upal Basu Roy, PhD, MPH to vice president of its Research.
In the elevated position, Dr Basu Roy will manage the company's extensive educational library as well as lead the Translational Research programme, the Career Development Award programme, the research funded through the ALK Positive partnership and the Patient Focused Research Center – Patient FoRCe.
Previously, Dr Basu Roy led community-based participatory research (CBPR) methodology in health sciences research, projects involving immigrants and minority populations,led diabetes education for Asian immigrants in New York City as well as educated minority populations about breast cancer screening in Queens, NY.
The company added that Dr Basu Roy has a PhD in Molecular and Cellular Biology from the University of Arizona and an MPH in Global Health Policy and Management from New York University.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies